The mutation in the PTH gene identified in a family with familial hypocalcemia not only provides a molecular genetic basis for understanding the pathogenesis of the disease, but also presents a highly promising potential for the development of clinically useful therapeutic agents targeting related diseases. This symposium has been organized to offer an opportunity for in-depth discussion of the research conducted thus far on ^R25CPTH.